{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sorafenib%2Bplacebo", "query": { "intervention": "Sorafenib+placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sorafenib%2Bplacebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T09:21:41.418Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00108953", "title": "A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin/Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2005-04", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108953" }, { "nct_id": "NCT00110994", "title": "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Melanoma" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2005-04", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 14, "location_summary": "Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110994" }, { "nct_id": "NCT00694291", "title": "Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2008-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694291" }, { "nct_id": "NCT00110019", "title": "Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mucosal Melanoma", "Recurrent Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 823, "start_date": "2005-06", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110019" }, { "nct_id": "NCT00865709", "title": "Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)", "type": "DRUG" }, { "name": "Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2009-03", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2014-12-11", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 5, "location_summary": "Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more", "locations": [ { "city": "Wichita", "state": "Kansas" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Brockton", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865709" }, { "nct_id": "NCT00606866", "title": "MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2004-07", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606866" }, { "nct_id": "NCT00855218", "title": "A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 307, "start_date": "2009-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 18, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00855218" }, { "nct_id": "NCT00300885", "title": "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel", "type": "DRUG" }, { "name": "Carboplatin plus Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 926, "start_date": "2006-02", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300885" }, { "nct_id": "NCT01911273", "title": "A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "PF-03446962", "type": "DRUG" }, { "name": "Best Supportive Care", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-10", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01911273" }, { "nct_id": "NCT00079612", "title": "Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2002-09", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-09-29T09:21:41.418Z", "location_count": 4, "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079612" } ] }